Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib and MEK-162 in Advanced CML and Ph+ Acute Leukemia
NCT02225574Phase 1Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2015
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of binimetinib in chronic myeloid leukemia (CML) and acute leukemia (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Mar 2015; status: terminated.
02
Drugs
binimetinib
03
Conditions
chronic myeloid leukemia (CML)acute leukemia
Beyond the preview
Go deeper on NCT02225574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02225574.